文献速递鼻科

阻抗控制多点射频消融治疗慢性鼻炎:随机对照试验

Impedance-Controlled Multipoint Radiofrequency Ablation for Chronic Rhinitis: A Randomized Controlled Trial.
PubMed 文献 · Int Forum Allergy Rhinol · 2026-01-08

这项前瞻性、多中心、单盲、优效性随机对照试验将132例慢性鼻炎患者按2:1随机分配至NEUROMARK后鼻神经消融组(88例)或假手术对照组(44例)。主要终点为90天随访时反映性总鼻部症状评分(rTNSS)应答率,活动组显著高于对照组(73.3% vs 35.0%,p<0.001),达到主要终点。活动组在rTNSS、后鼻滴漏、咳嗽、NOSE、mini-RQLQ及PHQ-9等次要指标上均较对照组有显著更大改善。

要点

  • NEUROMARK后鼻神经消融在90天rTNSS应答率上优于假手术(73.3% vs 35.0%)。
  • 活动组rTNSS、后鼻滴漏、咳嗽、NOSE、mini-RQLQ及PHQ-9改善均显著大于对照组。
  • NOSE应答率和mini-RQLQ应答率活动组亦显著高于对照组。

核心结论

  • NEUROMARK系统治疗慢性鼻炎优于假手术对照。

研究设计与样本

  • 前瞻性、多中心、单盲、优效性随机对照试验,132例受试者按2:1随机分配至活动治疗组(88例)和假手术对照组(44例)。

主要发现

  • 90天随访时活动组rTNSS应答率为73.3%(95%CI 64.0%-82.7%),对照组为35.0%(95%CI 20.2%-49.8%),p<0.001。
  • 活动组rTNSS变化为-4.0,对照组为-1.2,p<0.0001。
  • 活动组后鼻滴漏变化为-1.1,对照组为-0.3,p<0.001。
  • 活动组咳嗽变化为-0.9,对照组为-0.1,p<0.001。
  • 活动组NOSE评分变化为-32.2,对照组为-8.0,p<0.0001;活动组mini-RQLQ变化为-1.7,对照组为-0.5,p<0.0001;活动组PHQ-9变化为-3.0,对照组为-0.7,p=0.028。

关键数值与推荐

  • 主要终点为90天随访时rTNSS应答率组间比较,活动组显著高于对照组(p<0.001)。
  • NOSE应答率和mini-RQLQ应答率活动组显著高于对照组(p=0.001和p<0.0001)。

临床怎么用

  • 对于慢性鼻炎患者,可考虑采用NEUROMARK系统行后鼻神经消融以改善鼻部症状及生活质量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The purpose of this randomized controlled trial (RCT) was to demonstrate that posterior nasal nerve ablation treatment with the NEUROMARK System is superior to a sham control procedure in patients with chronic rhinitis. METHODS: In this prospective, multicenter, single-blinded, superiority RCT, 132 participants were randomized 2:1 to the active treatment arm (88) and sham control arm (44). The primary endpoint was the comparison of the reflective Total Nasal Symptom Score (rTNSS) responder rate between study arms at 90-day follow-up. Secondary efficacy outcomes included postnasal drip, chronic cough, Nasal Obstruction Symptom Evaluation (NOSE), mini-Rhinoconjunctivitis Quality of Life Questionnaire (mini-RQLQ), and Patient Health Questionnaire-9 (PHQ-9) (a depression assessment). RESULTS: The responder rate was significantly higher for the active treatment arm: 73.3% (95% confidence interval [CI], 64.0%-82.7%) compared to the sham control arm: 35.0% (95% CI, 20.2%-49.8%; p < 0.001). The primary endpoint was met, demonstrating the active treatment arm is superior to the sham control arm. The active treatment arm had significantly greater decreases (improvements) in the rTNSS (-4.0 vs. -1.2, p < 0.0001), postnasal drip (-1.1 vs. -0.3, p < 0.001), cough (-0.9 vs. -0.1, p < 0.001), NOSE score (-32.2 vs. -8.0, p < 0.0001), mini-RQLQ (-1.7 vs. -0.5, p < 0.0001), and PHQ-9 (-3.0 vs. -0.7, p = 0.028), compared to the sham control arm. The NOSE responder rate and mini-RQLQ responder rate were significantly higher for the active treatment arm than the sham control arm (p = 0.001 and p < 0.0001, respectively). CONCLUSION: Treatment for chronic rhinitis with the NEUROMARK System is superior to sham control.

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. Takashima M, Ow RA, Thrasher RD, et al. Impedance-Controlled Multipoint Radiofrequency Ablation for Chronic Rhinitis: A Randomized Controlled Trial. Int Forum Allergy Rhinol. 2026. PMID: 41508908. doi:10.1002/alr.70101

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。